Enasidenib - Celgene

Drug Profile

Enasidenib - Celgene

Alternative Names: AG 221 mesylate; AG-221; AGI 12910 mesylate; AGI-12910; CC-90007; IDHIFA

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Celgene Corporation
  • Class Antineoplastics; Propanols; Pyridines; Small molecules; Triazines
  • Mechanism of Action Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes
  • Phase I/II Solid tumours

Most Recent Events

  • 14 Feb 2018 Agios Pharmaceuticals has issued patents and pending patents covering IDH mutant product candidates, including enasidenib, in countries worldwide
  • 14 Feb 2018 Agios Pharmaceuticals plans phase III trial in Acute myeloid leukaemia with IDH1 or IDH2 mutation(Newly diagnosed, First-line therapy, Combination therapy) in the fourth quarter of 2018 (Trial profile 700291337)
  • 07 Jan 2018 Phase-II clinical trials in Myelodysplastic syndromes in USA (PO) (NCT03383575)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top